AR-42 significantly increased the sensitivity of CLL cells to TRAIL (figure 4A, n = 6), as has been shown for class I DAC inhibitors such as romidepsin [35], [36]. The gene discussed is TNFSF10; the disease is B-cell chronic lymphocytic leukemia.